Changes in cerebral glucose metabolism in patients with mild-to-moderate Alzheimer's disease: A pilot study with the Chinese herbal medicine fuzhisan
Changes in cerebral glucose metabolism in patients with mild-to-moderate Alzheimer's disease: A pilot study with the Chinese herbal medicine fuzhisan
复制标题
DOI：
10.1016/j.neulet.2011.06.036
复制
发表时间：
2011-08-21
影响因子：
2.5
通讯作者：
Wang, Desheng
中科院分区：
文献类型：
--
作者：
Bi, Min;Tong, Suijun;Wang, Desheng
本研究旨在探讨中药复栀散（FZS, 10 mg/d）对轻中度阿尔茨海默病（AD）患者脑糖代谢和神经心理指标的影响。这是一项为期12周、随机、双盲、安慰剂对照的先导研究。22名受试者被随机分配到接受FZS （n = 12）或安慰剂（n = 10）的组。使用正电子发射断层扫描（PET）研究基线和第12周时葡萄糖消耗的区域脑代谢率（rCMRglc）。我们分别采用阿尔茨海默病评估量表-认知亚量表（ADAS-Cog）和神经精神指数（NPI）评估FZS对认知和行为功能的临床疗效。与安慰剂相比，FZS在第12周显著提高ADAS-Cog评分和NPI评分。此外，FZS治疗有利于改善双侧颞叶和顶叶皮质、海马和后扣带回的rCMRglc。这些结果表明，FZS治疗可能对轻中度AD患者的认知、行为功能和rCMRgIc有积极影响。2011爱思唯尔爱尔兰有限公司版权所有。
The aim of this study was to investigate the effects of fuzhisan (FZS, 10 mg/day), a Chinese herbal medicine, on cerebral glucose metabolism and neuropsychological metrics in patients with mild-to-moderate Alzheimer's disease (AD). This was a 12-week, randomized, double-blind, placebo-controlled pilot study. Twenty-two subjects were randomly assigned to groups that received FZS (n = 12) or placebo (n = 10). Positron emission tomography (PET) was used to study the regional cerebral metabolic rate of glucose consumption (rCMRglc) at baseline and week 12. We evaluated the clinical efficacy of FZS on cognition and behavioral functions using the Alzheimer's Disease Assessment Scale-Cognitive subscale (ADAS-Cog) and the Neuropsychiatric Index (NPI), respectively. Compared with placebo, FZS significantly improved ADAS-Cog scores and NPI scores at week 12. Moreover, FZS treatment favorably improved rCMRglc in the bilateral temporal and parietal cortices, hippocampus, and posterior cingulate gyrus. These results suggest that FZS treatment may have a positive effect on cognition, behavioral functions, and rCMRgIc in mild-to-moderate AD patients. (C) 2011 Elsevier Ireland Ltd. All rights reserved.